Evercore ISI Initiates Coverage on Boston Scientific (BSX)

Research analysts at Evercore ISI started coverage on shares of Boston Scientific (NYSE:BSX) in a research note issued to investors on Wednesday, January 3rd, Marketbeat reports. The brokerage set an “in-line” rating and a $27.00 price target on the medical equipment provider’s stock. Evercore ISI’s price objective would indicate a potential downside of 1.68% from the stock’s current price.

Several other analysts also recently commented on BSX. Stifel Nicolaus reissued a “buy” rating and issued a $32.00 target price on shares of Boston Scientific in a research report on Monday, September 25th. Zacks Investment Research downgraded shares of Boston Scientific from a “hold” rating to a “sell” rating in a report on Monday, October 16th. BMO Capital Markets upped their price objective on shares of Boston Scientific from $30.00 to $32.00 and gave the stock an “outperform” rating in a report on Friday, October 27th. SunTrust Banks reaffirmed a “buy” rating and set a $34.00 price objective on shares of Boston Scientific in a report on Monday, October 2nd. Finally, Needham & Company LLC reiterated a “buy” rating and set a $32.00 target price on shares of Boston Scientific in a research note on Tuesday, October 3rd. Two analysts have rated the stock with a sell rating, four have issued a hold rating, twelve have given a buy rating and two have given a strong buy rating to the stock. Boston Scientific currently has an average rating of “Buy” and a consensus price target of $31.00.

Shares of Boston Scientific (BSX) opened at $27.46 on Wednesday. Boston Scientific has a 1-year low of $23.03 and a 1-year high of $29.93. The company has a current ratio of 0.72, a quick ratio of 0.50 and a debt-to-equity ratio of 0.58. The stock has a market cap of $37,710.00, a P/E ratio of 45.02, a PEG ratio of 1.96 and a beta of 0.96.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Thursday, October 26th. The medical equipment provider reported $0.31 EPS for the quarter, meeting the Zacks’ consensus estimate of $0.31. Boston Scientific had a net margin of 9.55% and a return on equity of 23.60%. The firm had revenue of $2.22 billion for the quarter, compared to the consensus estimate of $2.21 billion. During the same period in the previous year, the firm posted $0.27 earnings per share. The firm’s revenue was up 5.6% on a year-over-year basis. analysts forecast that Boston Scientific will post 1.25 EPS for the current fiscal year.

In other Boston Scientific news, SVP David A. Pierce sold 5,152 shares of the firm’s stock in a transaction that occurred on Tuesday, January 9th. The shares were sold at an average price of $27.00, for a total transaction of $139,104.00. Following the sale, the senior vice president now directly owns 38,116 shares in the company, valued at approximately $1,029,132. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Valley Gold Master Fund L. Sun bought 408,006 shares of the company’s stock in a transaction on Tuesday, November 28th. The shares were bought at an average price of $0.45 per share, for a total transaction of $183,602.70. Insiders sold a total of 96,585 shares of company stock worth $2,578,197 in the last ninety days. Insiders own 0.74% of the company’s stock.

A number of hedge funds have recently made changes to their positions in the business. Keybank National Association OH raised its holdings in shares of Boston Scientific by 4.6% in the second quarter. Keybank National Association OH now owns 28,752 shares of the medical equipment provider’s stock valued at $797,000 after purchasing an additional 1,277 shares during the last quarter. Commerce Bank grew its stake in shares of Boston Scientific by 17.7% in the second quarter. Commerce Bank now owns 9,803 shares of the medical equipment provider’s stock valued at $272,000 after buying an additional 1,471 shares in the last quarter. Bronfman E.L. Rothschild L.P. grew its stake in shares of Boston Scientific by 14.3% in the second quarter. Bronfman E.L. Rothschild L.P. now owns 5,761 shares of the medical equipment provider’s stock valued at $160,000 after buying an additional 720 shares in the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS grew its stake in shares of Boston Scientific by 0.6% in the second quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 101,738 shares of the medical equipment provider’s stock valued at $2,820,000 after buying an additional 596 shares in the last quarter. Finally, IFM Investors Pty Ltd grew its stake in shares of Boston Scientific by 34.7% in the second quarter. IFM Investors Pty Ltd now owns 37,053 shares of the medical equipment provider’s stock valued at $1,027,000 after buying an additional 9,538 shares in the last quarter. Hedge funds and other institutional investors own 90.36% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Evercore ISI Initiates Coverage on Boston Scientific (BSX)” was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this story on another publication, it was copied illegally and reposted in violation of international trademark & copyright law. The legal version of this story can be accessed at https://www.dispatchtribunal.com/2018/01/13/evercore-isi-begins-coverage-on-boston-scientific-bsx.html.

Boston Scientific Company Profile

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.

Analyst Recommendations for Boston Scientific (NYSE:BSX)

Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply